These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P MAbs; 2015; 7(4):743-51. PubMed ID: 25970007 [TBL] [Abstract][Full Text] [Related]
3. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319 [TBL] [Abstract][Full Text] [Related]
4. In vitro functional characterization of feline IgGs. Strietzel CJ; Bergeron LM; Oliphant T; Mutchler VT; Choromanski LJ; Bainbridge G Vet Immunol Immunopathol; 2014 Apr; 158(3-4):214-23. PubMed ID: 24560097 [TBL] [Abstract][Full Text] [Related]
5. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Voice JK; Lachmann PJ Eur J Immunol; 1997 Oct; 27(10):2514-23. PubMed ID: 9368604 [TBL] [Abstract][Full Text] [Related]
6. Human monocyte-mediated cytotoxicity towards erythrocytes induced by hybrid mouse monoclonal antibodies: effect of antibody binding valency on IgG-Fc gamma R interaction. Koolwijk P; Van de Winkel JG; Otten I; Bast BJ Immunology; 1992 Feb; 75(2):336-42. PubMed ID: 1532380 [TBL] [Abstract][Full Text] [Related]
7. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Michaelsen TE; Aase A; Norderhaug L; Sandlie I Mol Immunol; 1992 Mar; 29(3):319-26. PubMed ID: 1557042 [TBL] [Abstract][Full Text] [Related]
8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548 [TBL] [Abstract][Full Text] [Related]
9. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625 [TBL] [Abstract][Full Text] [Related]
10. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. van de Winkel JG; Capel PJ Immunol Today; 1993 May; 14(5):215-21. PubMed ID: 8517920 [TBL] [Abstract][Full Text] [Related]
11. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310 [TBL] [Abstract][Full Text] [Related]
12. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420 [TBL] [Abstract][Full Text] [Related]
13. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes. Hadley AG; Zupanska B; Kumpel BM; Leader KA Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095 [TBL] [Abstract][Full Text] [Related]
14. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853 [TBL] [Abstract][Full Text] [Related]
15. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584 [TBL] [Abstract][Full Text] [Related]
16. [Immunology in clinical practice. X. IgG receptors: structure, function and immunotherapy]. van der Pol WL; van de Winkel JG Ned Tijdschr Geneeskd; 1998 Feb; 142(7):335-40. PubMed ID: 9562738 [TBL] [Abstract][Full Text] [Related]
17. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830 [TBL] [Abstract][Full Text] [Related]
18. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. Davis PM; Abraham R; Xu L; Nadler SG; Suchard SJ J Rheumatol; 2007 Nov; 34(11):2204-10. PubMed ID: 17787038 [TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant IFN-gamma (rIFN-gamma) on the mechanism of human macrophage IgG FcRI-mediated cytotoxicity. rIFN-gamma decreases inhibition by cytophilic human IgG and changes the cytolytic mechanism. Van Schie RC; Verstraten RG; Van de Winkel JG; Tax WJ; de Mulder PH J Immunol; 1992 Jan; 148(1):169-76. PubMed ID: 1530794 [TBL] [Abstract][Full Text] [Related]
20. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]